IAPs and Resistance to Death Receptors in Cancer
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | IAPs and Resistance to Death Receptors in Cancer |
| Type de publication | Book Chapter |
| Year of Publication | 2017 |
| Auteurs | Dubrez L, Fulda S |
| Editor | Micheau O |
| Book Title | TRAIL, FAS LIGAND, TNF AND TLR3 IN CANCER |
| Series Title | Resistance to Targeted Anti-Cancer Therapeutics |
| Volume | 12 |
| Pagination | 59-77 |
| Publisher | SPRINGER INTERNATIONAL PUBLISHING AG |
| City | GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND |
| ISBN Number | 978-3-319-56805-8; 978-3-319-56804-1 |
| ISBN | 2196-5501 |
| Mots-clés | Apoptosis, IAPS, Necroptosis, NF-kappa B, RIPK1, Smac mimetics |
| Résumé | Since their identification in mammal cells, IAPs emerged have as potent regulators of death receptor signalling pathways, determining the cell fate in response to receptor stimulation. Among IAPs, cIAP1 and cIAP2 are active components of receptor-associated signalling complexes able to promote the activation of ubiquitin-dependent survival signalling pathways. For its part, XIAP is an important regulator of caspase activity, determining the apoptotic signalling pathway engaged after death receptor stimulation. The use of IAP antagonists is a promising strategy in order to overcome the resistance of tumor cells to death receptor stimulation. |
| DOI | 10.1007/978-3-319-56805-8_3 |